This study aims to evaluate the role of artificial intelligence (AI) in predicting disease stage and survival in patients diagnosed with non-small cell lung cancer (NSCLC). Using a retrospective design, the research will analyze radiologic imaging data (PET-CT and chest CT) and corresponding histopathological results of patients who underwent lung cancer surgery at Ondokuz Mayis University Hospital. The goal is to develop and validate a deep learning-based AI model that can automatically assess preoperative radiologic features and estimate postoperative tumor stage and survival outcomes. By integrating radiologic data with confirmed pathological diagnoses, the AI system is expected to provide clinical decision support that can improve diagnostic speed, reduce human error, and help clinicians predict prognosis more accurately. This study does not involve any experimental treatment or prospective follow-up of patients. All data will be collected from existing medical records. The findings may contribute to the digital transformation of healthcare and promote the use of AI tools in thoracic oncology.
Study Type
OBSERVATIONAL
Enrollment
150
This is not a therapeutic or diagnostic intervention. The study uses a retrospective dataset of radiologic and pathological records to train and validate a deep learning model designed to predict tumor stage and survival in patients with non-small cell lung cancer (NSCLC). No experimental procedure is applied to participants.
Development of AI Model for Predicting Tumor Stage and Survival
The primary outcome of this study is to develop and validate a deep learning-based artificial intelligence model that can predict postoperative tumor stage and survival in patients with non-small cell lung cancer using preoperative PET-CT and chest CT imaging data. The primary outcome will be considered achieved when at least 80% of the planned patient dataset (150 patients) has been successfully included and used for model development.
Time frame: From data extraction to completion of model training and validation (estimated by September 2025)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.